Biotechnology

Dermata Therapeutics

Dermata Therapeutics released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.6483 (forecast USD -1.59)

Dermata Therapeutics released FY2025 9 Months Earnings on November 14 (EST) with actual revenue of USD 0 and EPS of USD -8.7845

Dermata Therapeutics released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.66 (forecast USD -2.9)

Dermata Therapeutics released FY2025 Semi-Annual Earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -6.2793

Dermata Therapeutics Holds Annual Shareholders Meeting

Dermata Therapeutics Inc. Obtains Australian Patent

Dermata Therapeutics Inc. Releases Progress Presentation on Topical Skin Treatments

Maxim Group Adjusts Dermata Therapeutics' Stock Rating

Dermata Therapeutics Inc plans to submit Xyngari's NDA application in 2028

Dermata Therapeutics Initiates Production for XYNGARI's Phase 3 STAR-2 Trial

Dermata Therapeutics released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.4689 (forecast USD -4.5)

Dermata Therapeutics Reports Positive Results for Acne Treatment Trial and Partners with Revance Therapeutics

Dermata Therapeutics Inc announces preliminary results of XYNGARI Phase 3 trial

Dermata Therapeutics Inc XYNGARI™ Phase 3 Trial Preliminary Data Meets All Primary Endpoints

Dermata Therapeutics released FY2024 annual earnings on March 17 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -8.0322 USD (forecast -14.78 USD)

Dermata Therapeutics released FY2024 Q4 earnings on March 17 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -9.1688 (forecast USD -15)

Dermata Therapeutics Raises $2.55 Million in Private Financing

Dermata Therapeutics released FY2024 Q3 earnings on November 13 (EST), with actual revenue of 0 USD and EPS of -2.041 USD (forecast EPS -2.64 USD)

Dermata Therapeutics released FY2024 9 Months Earnings on November 13 (EST), with actual revenue of USD 0 and EPS of USD -132.82

Dermata Therapeutics released FY2024 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -41.8154 (forecast USD -37.9)

Haoxin

Sidus Space

Jyong Biotech

Starfighters Space

Autozi Internet Tech Global

Hycroft Mining

Creative Media & Community Trust

Velo3D

Iczoom

Adeia

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap